<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01974323</url>
  </required_header>
  <id_info>
    <org_study_id>225678-007</org_study_id>
    <nct_id>NCT01974323</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris</brief_title>
  <official_title>A Safety and Efficacy Study to Compare Dapsone Dermal Gel With Vehicle Control in Patients With Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of dapsone gel versus vehicle control in
      patients with acne vulgaris.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, double-blind, randomized, parallel-group, vehicle-controlled study to
      assess the safety and efficacy of dapsone 7.5% gel versus vehicle administered topically once
      daily for 12 weeks in patients with acne vulgaris.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients With a Score of 0 (None) or 1 (Minimal) on the 5-point Global Acne Assessment Score (GAAS)</measure>
    <time_frame>Week 12</time_frame>
    <description>The Investigator evaluated the patient's acne severity using the 5-point GAAS scale with 0 being none and 4 being severe. The complete scale is as follow: Grade 0 (none) = No evidence of facila acne vulgaris; Grade 1 (minimal) = Few noninflammatory lesions (comedones) are present, a few inflammatory lesions (papules/pustules) may be present, no nodulo-cyctic lesions are allowed; Grade 2 (mild) = Several to many noninflammatory lesions (comedones) are present, a few inflammatory lesions (papules/pustules) are present, no nodulo-cystic lesions are allowed; Grade 3 (moderate) = Many noninflammatory (comedones) and inflammatory lesions (papules/pustules) are present, no nodulo-cystic lesions are allowed; Grade 4 (severe) = Significant degree of inflammatory disease, papules/pustules are a predominant feature, a few nodulo-cystic lesions may be present, comedones may be present.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Inflammatory Facial Lesion Counts</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The Investigator evaluated the patient's inflammatory lesions (papule, pustule and nodule/cyst). A negative change from baseline indicates a reduction in lesion counts (improvement) and a positive change from baseline indicates an increase in lesion counts (worsening).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Noninflammatory Facial Lesion Counts</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The Investigator evaluated the patient's noninflammatory lesions (papule, pustule and nodule/cyst). A negative change from baseline indicates a reduction in lesion counts (improvement) and a positive change from baseline indicates an increase in lesion counts (worsening).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Lesion Counts</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The Investigator evaluated the patient's inflammatory (papule, pustule and nodule/cyst) and non-inflammatory (blackhead and whitehead) lesions. A papule is a small, red, solid elevation less than 1.0 cm in diameter, a pustule is a small, circumscribed elevation of the skin that contains yellow-white exudate and a nodule/cyst is a circumscribed, elevated, solid lesion generally more than 0.5 cm in diameter with palpable depth. The total lesion count was the sum of the inflammatory and non-inflammatory lesion counts. A negative change from baseline indicates a reduction in lesion counts (improvement) and a positive change from baseline indicates an increase in lesion counts (worsening).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Total Lesion Counts</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The Investigator evaluated the patient's Inflammatory (papule, pustule and nodule/cyst) and Non-inflammatory (blackhead and whitehead) lesions. A papule is a small, red, solid elevation less than 1.0 cm in diameter, a pustule is a small, circumscribed elevation of the skin that contains yellow-white exudate and a nodule/cyst is a circumscribed, elevated, solid lesion generally more than 0.5 cm in diameter with palpable depth. The total lesion count was the sum of the inflammatory and non-inflammatory lesion counts. A negative percent change from baseline indicates a reduction in lesion counts (improvement) and a positive percent change from baseline indicates an increase in lesion counts (worsening).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Reporting &quot;Very Good&quot; or &quot;Excellent&quot; on Item 10 of the 5-Point Acne Symptom Impact Scale (ASIS)</measure>
    <time_frame>Week 12</time_frame>
    <description>The patient assessed the impact of their acne vulgaris on the look of their face using item 10 on the 5-point ASIS. Item 10 scores range from 1 (Excellent) to 5 (Bad). The percentage of patients who had an ASIS score of 4 (Fair) or 5 (Bad) at baseline and who reported &quot;Very good&quot; or &quot;Excellent&quot; at Week 12 are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the 9-Item ASIS Sign Domain Score</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The patient assessed signs of acne vulgaris using the ASIS. The sign domain is a composite of 9 items of the 17 items on the overall scale. Each of the items is assessed on a 5-point scale: 0 (best) to 4 (worst). The sign domain score is calculated as the average of the 9 items for a total possible score of 0 to 4. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Reporting at Least a 1-Grade Improvement From Baseline in Facial Oiliness on a the 5-Point ASIS Scale</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The patient assessed their facial oiliness using item 1 on the 5-point ASIS. Item 1 scores ranged from 0 (Not at all oily) to 4 (Very oily). The percentage of patients who reported at least a 1-grade improvement from baseline in their facial oiliness are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Reporting at Least a 1-Grade Improvement From Baseline in Facial Redness on a the 5-Point ASIS Scale</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The patient assessed their facial redness using item 8 on the 5-point ASIS. Item 8 scores ranged from 0 (Not at all red) to 4 (Very red). The percentage of patients who reported at least a 1-grade improvement from baseline in their facial redness are reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2238</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Dapsone Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dapsone Gel Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapsone Gel</intervention_name>
    <description>Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.</description>
    <arm_group_label>Dapsone Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapsone Gel Vehicle</intervention_name>
    <description>Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.</description>
    <arm_group_label>Dapsone Gel Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of acne vulgaris

          -  Willing to avoid excessive or prolonged exposure to ultraviolet light (eg, sunlight,
             tanning beds) throughout the study

        Exclusion Criteria:

          -  Severe cystic acne, acne conglobata, acne fulminans, or secondary acne

          -  Use of phototherapy devices (eg, ClearLight™), energy-based devices, adhesive
             cleansing strips (eg, Pond's®, Biore®), or cosmetic procedures (eg, facials, peeling,
             comedo extraction) in the past week

          -  Use of anti-inflammatory medications, salicylic acid; corticosteroids, antibiotics,
             antibacterials (including benzoyl peroxide-containing products [eg, benzamycin]),
             retinoids; other topical acne treatments (eg, photodynamic therapy, medicated soaps
             such as those containing benzoyl peroxide, salicylic acid, sulfur, or sodium
             sulfacetamide) in the past 2 weeks

          -  Use of birth control pills strictly for acne control
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2013</study_first_submitted>
  <study_first_submitted_qc>October 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2013</study_first_posted>
  <results_first_submitted>May 5, 2016</results_first_submitted>
  <results_first_submitted_qc>December 13, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 6, 2017</results_first_posted>
  <disposition_first_submitted>September 30, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>September 30, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 21, 2015</disposition_first_posted>
  <last_update_submitted>December 13, 2016</last_update_submitted>
  <last_update_submitted_qc>December 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapsone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dapsone Gel</title>
          <description>Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Dapsone Gel Vehicle</title>
          <description>Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1118"/>
                <participants group_id="P2" count="1120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1026"/>
                <participants group_id="P2" count="1027"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="93"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other Reasons</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Personal Reasons</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dapsone Gel</title>
          <description>Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Dapsone Gel Vehicle</title>
          <description>Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1118"/>
            <count group_id="B2" value="1120"/>
            <count group_id="B3" value="2238"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.5" spread="8.15"/>
                    <measurement group_id="B2" value="20.4" spread="7.38"/>
                    <measurement group_id="B3" value="20.4" spread="7.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="618"/>
                    <measurement group_id="B2" value="631"/>
                    <measurement group_id="B3" value="1249"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="500"/>
                    <measurement group_id="B2" value="489"/>
                    <measurement group_id="B3" value="989"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With a Score of 0 (None) or 1 (Minimal) on the 5-point Global Acne Assessment Score (GAAS)</title>
        <description>The Investigator evaluated the patient's acne severity using the 5-point GAAS scale with 0 being none and 4 being severe. The complete scale is as follow: Grade 0 (none) = No evidence of facila acne vulgaris; Grade 1 (minimal) = Few noninflammatory lesions (comedones) are present, a few inflammatory lesions (papules/pustules) may be present, no nodulo-cyctic lesions are allowed; Grade 2 (mild) = Several to many noninflammatory lesions (comedones) are present, a few inflammatory lesions (papules/pustules) are present, no nodulo-cystic lesions are allowed; Grade 3 (moderate) = Many noninflammatory (comedones) and inflammatory lesions (papules/pustules) are present, no nodulo-cystic lesions are allowed; Grade 4 (severe) = Significant degree of inflammatory disease, papules/pustules are a predominant feature, a few nodulo-cystic lesions may be present, comedones may be present.</description>
        <time_frame>Week 12</time_frame>
        <population>Intent-to-Treat: all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Dapsone Gel</title>
            <description>Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Dapsone Gel Vehicle</title>
            <description>Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With a Score of 0 (None) or 1 (Minimal) on the 5-point Global Acne Assessment Score (GAAS)</title>
          <description>The Investigator evaluated the patient's acne severity using the 5-point GAAS scale with 0 being none and 4 being severe. The complete scale is as follow: Grade 0 (none) = No evidence of facila acne vulgaris; Grade 1 (minimal) = Few noninflammatory lesions (comedones) are present, a few inflammatory lesions (papules/pustules) may be present, no nodulo-cyctic lesions are allowed; Grade 2 (mild) = Several to many noninflammatory lesions (comedones) are present, a few inflammatory lesions (papules/pustules) are present, no nodulo-cystic lesions are allowed; Grade 3 (moderate) = Many noninflammatory (comedones) and inflammatory lesions (papules/pustules) are present, no nodulo-cystic lesions are allowed; Grade 4 (severe) = Significant degree of inflammatory disease, papules/pustules are a predominant feature, a few nodulo-cystic lesions may be present, comedones may be present.</description>
          <population>Intent-to-Treat: all randomized patients</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1118"/>
                <count group_id="O2" value="1120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.8"/>
                    <measurement group_id="O2" value="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Inflammatory Facial Lesion Counts</title>
        <description>The Investigator evaluated the patient's inflammatory lesions (papule, pustule and nodule/cyst). A negative change from baseline indicates a reduction in lesion counts (improvement) and a positive change from baseline indicates an increase in lesion counts (worsening).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Intent-to-Treat: all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Dapsone Gel</title>
            <description>Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Dapsone Gel Vehicle</title>
            <description>Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Inflammatory Facial Lesion Counts</title>
          <description>The Investigator evaluated the patient's inflammatory lesions (papule, pustule and nodule/cyst). A negative change from baseline indicates a reduction in lesion counts (improvement) and a positive change from baseline indicates an increase in lesion counts (worsening).</description>
          <population>Intent-to-Treat: all randomized patients</population>
          <units>Number of Inflammatory Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1118"/>
                <count group_id="O2" value="1120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6" spread="0.23"/>
                    <measurement group_id="O2" value="30.0" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.6" spread="0.35"/>
                    <measurement group_id="O2" value="-14.0" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Noninflammatory Facial Lesion Counts</title>
        <description>The Investigator evaluated the patient's noninflammatory lesions (papule, pustule and nodule/cyst). A negative change from baseline indicates a reduction in lesion counts (improvement) and a positive change from baseline indicates an increase in lesion counts (worsening).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Intent-to-Treat: all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Dapsone Gel</title>
            <description>Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Dapsone Gel Vehicle</title>
            <description>Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Noninflammatory Facial Lesion Counts</title>
          <description>The Investigator evaluated the patient's noninflammatory lesions (papule, pustule and nodule/cyst). A negative change from baseline indicates a reduction in lesion counts (improvement) and a positive change from baseline indicates an increase in lesion counts (worsening).</description>
          <population>Intent-to-Treat: all randomized patients</population>
          <units>Number of Noninflammatory Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1118"/>
                <count group_id="O2" value="1120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7" spread="0.46"/>
                    <measurement group_id="O2" value="46.7" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.8" spread="0.55"/>
                    <measurement group_id="O2" value="-18.7" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Lesion Counts</title>
        <description>The Investigator evaluated the patient's inflammatory (papule, pustule and nodule/cyst) and non-inflammatory (blackhead and whitehead) lesions. A papule is a small, red, solid elevation less than 1.0 cm in diameter, a pustule is a small, circumscribed elevation of the skin that contains yellow-white exudate and a nodule/cyst is a circumscribed, elevated, solid lesion generally more than 0.5 cm in diameter with palpable depth. The total lesion count was the sum of the inflammatory and non-inflammatory lesion counts. A negative change from baseline indicates a reduction in lesion counts (improvement) and a positive change from baseline indicates an increase in lesion counts (worsening).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Intent-to-Treat: all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Dapsone Gel</title>
            <description>Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Dapsone Gel Vehicle</title>
            <description>Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Lesion Counts</title>
          <description>The Investigator evaluated the patient's inflammatory (papule, pustule and nodule/cyst) and non-inflammatory (blackhead and whitehead) lesions. A papule is a small, red, solid elevation less than 1.0 cm in diameter, a pustule is a small, circumscribed elevation of the skin that contains yellow-white exudate and a nodule/cyst is a circumscribed, elevated, solid lesion generally more than 0.5 cm in diameter with palpable depth. The total lesion count was the sum of the inflammatory and non-inflammatory lesion counts. A negative change from baseline indicates a reduction in lesion counts (improvement) and a positive change from baseline indicates an increase in lesion counts (worsening).</description>
          <population>Intent-to-Treat: all randomized patients</population>
          <units>Total Lesion Counts</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1118"/>
                <count group_id="O2" value="1120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.4" spread="0.56"/>
                    <measurement group_id="O2" value="76.9" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.2" spread="0.76"/>
                    <measurement group_id="O2" value="-32.3" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Total Lesion Counts</title>
        <description>The Investigator evaluated the patient's Inflammatory (papule, pustule and nodule/cyst) and Non-inflammatory (blackhead and whitehead) lesions. A papule is a small, red, solid elevation less than 1.0 cm in diameter, a pustule is a small, circumscribed elevation of the skin that contains yellow-white exudate and a nodule/cyst is a circumscribed, elevated, solid lesion generally more than 0.5 cm in diameter with palpable depth. The total lesion count was the sum of the inflammatory and non-inflammatory lesion counts. A negative percent change from baseline indicates a reduction in lesion counts (improvement) and a positive percent change from baseline indicates an increase in lesion counts (worsening).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Intent-to-Treat: all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Dapsone Gel</title>
            <description>Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Dapsone Gel Vehicle</title>
            <description>Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Total Lesion Counts</title>
          <description>The Investigator evaluated the patient's Inflammatory (papule, pustule and nodule/cyst) and Non-inflammatory (blackhead and whitehead) lesions. A papule is a small, red, solid elevation less than 1.0 cm in diameter, a pustule is a small, circumscribed elevation of the skin that contains yellow-white exudate and a nodule/cyst is a circumscribed, elevated, solid lesion generally more than 0.5 cm in diameter with palpable depth. The total lesion count was the sum of the inflammatory and non-inflammatory lesion counts. A negative percent change from baseline indicates a reduction in lesion counts (improvement) and a positive percent change from baseline indicates an increase in lesion counts (worsening).</description>
          <population>Intent-to-Treat: all randomized patients</population>
          <units>Percent Change in Lesion Count</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1118"/>
                <count group_id="O2" value="1120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.9" spread="0.97"/>
                    <measurement group_id="O2" value="-43.2" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Reporting &quot;Very Good&quot; or &quot;Excellent&quot; on Item 10 of the 5-Point Acne Symptom Impact Scale (ASIS)</title>
        <description>The patient assessed the impact of their acne vulgaris on the look of their face using item 10 on the 5-point ASIS. Item 10 scores range from 1 (Excellent) to 5 (Bad). The percentage of patients who had an ASIS score of 4 (Fair) or 5 (Bad) at baseline and who reported “Very good” or “Excellent” at Week 12 are reported.</description>
        <time_frame>Week 12</time_frame>
        <population>Intent-to-Treat: all randomized patients with data at this time point</population>
        <group_list>
          <group group_id="O1">
            <title>Dapsone Gel</title>
            <description>Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Dapsone Gel Vehicle</title>
            <description>Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Reporting &quot;Very Good&quot; or &quot;Excellent&quot; on Item 10 of the 5-Point Acne Symptom Impact Scale (ASIS)</title>
          <description>The patient assessed the impact of their acne vulgaris on the look of their face using item 10 on the 5-point ASIS. Item 10 scores range from 1 (Excellent) to 5 (Bad). The percentage of patients who had an ASIS score of 4 (Fair) or 5 (Bad) at baseline and who reported “Very good” or “Excellent” at Week 12 are reported.</description>
          <population>Intent-to-Treat: all randomized patients with data at this time point</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="926"/>
                <count group_id="O2" value="961"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2"/>
                    <measurement group_id="O2" value="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the 9-Item ASIS Sign Domain Score</title>
        <description>The patient assessed signs of acne vulgaris using the ASIS. The sign domain is a composite of 9 items of the 17 items on the overall scale. Each of the items is assessed on a 5-point scale: 0 (best) to 4 (worst). The sign domain score is calculated as the average of the 9 items for a total possible score of 0 to 4. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Intent-to-Treat: all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Dapsone Gel</title>
            <description>Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Dapsone Gel Vehicle</title>
            <description>Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the 9-Item ASIS Sign Domain Score</title>
          <description>The patient assessed signs of acne vulgaris using the ASIS. The sign domain is a composite of 9 items of the 17 items on the overall scale. Each of the items is assessed on a 5-point scale: 0 (best) to 4 (worst). The sign domain score is calculated as the average of the 9 items for a total possible score of 0 to 4. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.</description>
          <population>Intent-to-Treat: all randomized patients</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1118"/>
                <count group_id="O2" value="1120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" spread="0.627"/>
                    <measurement group_id="O2" value="2.07" spread="0.612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.74" spread="0.700"/>
                    <measurement group_id="O2" value="-0.68" spread="0.675"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Reporting at Least a 1-Grade Improvement From Baseline in Facial Oiliness on a the 5-Point ASIS Scale</title>
        <description>The patient assessed their facial oiliness using item 1 on the 5-point ASIS. Item 1 scores ranged from 0 (Not at all oily) to 4 (Very oily). The percentage of patients who reported at least a 1-grade improvement from baseline in their facial oiliness are reported.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Intent-to-Treat: all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Dapsone Gel</title>
            <description>Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Dapsone Gel Vehicle</title>
            <description>Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Reporting at Least a 1-Grade Improvement From Baseline in Facial Oiliness on a the 5-Point ASIS Scale</title>
          <description>The patient assessed their facial oiliness using item 1 on the 5-point ASIS. Item 1 scores ranged from 0 (Not at all oily) to 4 (Very oily). The percentage of patients who reported at least a 1-grade improvement from baseline in their facial oiliness are reported.</description>
          <population>Intent-to-Treat: all randomized patients</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1118"/>
                <count group_id="O2" value="1120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.5"/>
                    <measurement group_id="O2" value="49.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Reporting at Least a 1-Grade Improvement From Baseline in Facial Redness on a the 5-Point ASIS Scale</title>
        <description>The patient assessed their facial redness using item 8 on the 5-point ASIS. Item 8 scores ranged from 0 (Not at all red) to 4 (Very red). The percentage of patients who reported at least a 1-grade improvement from baseline in their facial redness are reported.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Intent-to-Treat: all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Dapsone Gel</title>
            <description>Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Dapsone Gel Vehicle</title>
            <description>Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Reporting at Least a 1-Grade Improvement From Baseline in Facial Redness on a the 5-Point ASIS Scale</title>
          <description>The patient assessed their facial redness using item 8 on the 5-point ASIS. Item 8 scores ranged from 0 (Not at all red) to 4 (Very red). The percentage of patients who reported at least a 1-grade improvement from baseline in their facial redness are reported.</description>
          <population>Intent-to-Treat: all randomized patients</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1118"/>
                <count group_id="O2" value="1120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.8"/>
                    <measurement group_id="O2" value="52.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The Safety Population was used to assess adverse events and serious adverse events. The Safety Population included all patients who were treated with at least 1 application of study treatment</desc>
      <group_list>
        <group group_id="E1">
          <title>Dapsone Gel</title>
          <description>Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Dapsone Gel Vehicle</title>
          <description>Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Peritoneal Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1118"/>
              </event>
              <event>
                <sub_title>Helicobacter Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute Myeloid Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion Spontaneous</sub_title>
                <description>FEMALES ONLY</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="618"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="631"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alchoholism</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1118"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax Spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1118"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1118"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head,</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

